miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. - Wikidata - awgldk - TriplyDB

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

http://www.wikidata.org/entity/Q39215725

about

MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives Key fibrogenic mediators: old players. Renin–angiotensin system TGF-β/Smad signaling in renal fibrosis MicroRNA-21 in the pathogenesis of acute kidney injury MicroRNAs in Diabetic Kidney Disease The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitus TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation MicroRNAs in idiopathic pulmonary fibrosis: involvement in pathogenesis and potential use in diagnosis and therapeutics Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways Plasma miR-21 expression: an indicator for the severity of Type 2 diabetes with diabetic retinopathy.Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.Serum levels of WNT1-inducible signaling pathway protein-1 (WISP-1): a noninvasive biomarker of renal fibrosis in subjects with chronic kidney disease.The role of microRNAs in diabetic nephropathy.MicroRNAs and their applications in kidney diseases Characterization of microRNA expression profiles in Leishmania-infected human phagocytes.Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy.MicroRNAs in renal fibrosis.Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling.Combination of active components of Xiexin decoction ameliorates renal fibrosis through the inhibition of NF-κB and TGF-β1/Smad pathways in db/db diabetic mice Influence of erythropoietin on microvesicles derived from mesenchymal stem cells protecting renal function of chronic kidney disease Different regulation of miR-29a-3p in glomeruli and tubules in an experimental model of angiotensin II-dependent hypertension: potential role in renal fibrosis.Circulating TGF-β1-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes.Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis Upregulation of Mir-21 Levels in the Vitreous Humor Is Associated with Development of Proliferative Vitreoretinal Disease.Stem Cell-Derived, microRNA-Carrying Extracellular Vesicles: A Novel Approach to Interfering with Mesangial Cell Collagen Production in a Hyperglycaemic Setting.MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy Uremic Toxicity of Advanced Glycation End Products in CKD.Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice.Treatment of renal fibrosis by rebalancing TGF-β/Smad signaling with the combination of asiatic acid and naringenin.MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications.Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile Anti-diabetic activities of catalpol in db/db mice.The regulation and function of microRNAs in kidney diseases.Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan.

P2860

Q26766102-32E5A5A6-7434-4E7B-9E9D-4B0F3C21A638 Q26771750-2E99D4D3-2739-413B-A47E-4282E54E8222 Q26796631-63CCCE0D-652C-4E65-B05D-A02A63FD130F Q26851198-6F52523F-4BCB-447C-969B-C5D45DBFF52B Q26862709-02E71C10-9277-48C2-9E69-E5987BBAB36F Q27002171-8B887925-46A4-4A48-A134-2EB8B6163473 Q27027262-F81750C2-F38F-446A-B7B2-590BBE427721 Q28067425-30DD7805-9C47-465F-B8AB-8BA31580EFCC Q28068338-8B5B78B6-0F7A-4ACF-B75C-4C4ABAC56CF7 Q28083164-B59A4D13-A053-4453-9C86-3753B7595CD9 Q28354033-7F11214C-B05A-46EC-8A3A-5A5DE48E5729 Q28975627-FB66ECE9-D346-4D3F-9E8D-FC6D41C1143F Q30239808-706189EB-DD7D-4B90-84A4-8B0F939A2953 Q30405346-1B26C852-67C1-42D6-97A0-B802993C052F Q33792645-3F640B82-1CAE-4167-AF69-88374A392381 Q33806760-2985D6F8-7D8F-4E99-8069-3A84AEDBBEBB Q33850279-79AB57CD-6A08-42DF-9724-AB8A638E5739 Q34195411-9A9CD38E-B1E2-461D-809E-9869098EF307 Q34696427-DD49A42C-688C-4057-8AA1-45897E0315FC Q34870671-3884F461-18CF-424E-A2C3-BA7214FF3700 Q35076442-3ABC128D-7CDB-4025-8BA5-ED3CB6B5A7F9 Q35104478-6F747494-6EC5-4B54-8B08-49D05911B68F Q35124896-017AFC48-C6C9-4AC8-8304-2A8001F0296E Q35585328-F578CD93-FC5A-43D0-AB9F-140C06C94CEE Q35747607-351DF998-889C-477E-A2DC-95C1BB9BD15A Q35877447-4E11BF9B-324E-4878-A37D-0041BB958EF7 Q35973844-FE966548-D457-4D96-9DB8-D544D5EEFDA4 Q36004612-8C9E8478-D5DF-4754-918C-009CB333257F Q36063043-D4BF6B72-CCB8-404D-BF3F-FA1A33EC05ED Q36127809-04BC839C-6E73-433B-8FE0-A0A849D8F03A Q36166755-BB95EEB6-3822-42D5-BFD8-985271E300BC Q36281620-2065ABA4-3B05-4792-9790-0C8E4461EE5D Q36514906-3DFF0FEC-6355-4985-B3FF-BDAAE59ED52E Q36530849-A9D9A9EA-607B-45BC-A9AE-4AE1E211D4E2 Q36545653-C43B3853-6521-45D7-AF94-81A7D930C67D Q36546363-FABAF081-039B-441D-A8DB-6C648B583FDC Q36555317-113A2E54-83F3-4EF9-8A13-2CC23B618DEB Q36627589-D19569E9-57A7-4D24-BA6A-A75B063AAC7D Q36960910-6973D5F0-E97B-4B45-A712-6649568532BE Q36970073-2AA0BD73-454F-487D-8F46-C566F8D9380B

P2860

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

http://www.wikidata.org/entity/Q39215725

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@en

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@nl

type

label

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@en

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@nl

prefLabel

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@en

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.

@nl

P1433

Q39215725-86077DF8-48A3-4975-9422-6CD86A43A11D

P1476

Q39215725-D1AD7D25-1DCA-4BA2-88F3-C35DF2B01992

P2093

Q39215725-168D0A65-DB4D-4213-9DCE-D0BF9B6598EF

Q39215725-40AD5E2C-C3D3-4D0B-A453-861C0FA3CEAC

Q39215725-5B38CF1B-2BD3-4339-9FC0-45092C502759

Q39215725-A52A2E39-9453-4FD5-8FA0-FA4F560FDFE8

Q39215725-C2832300-4E82-4B33-A590-CCA0D542360B

P2860

Q39215725-069DC831-7E98-425B-8A66-0683EBD66437

Q39215725-12ABA18A-D090-4478-93EB-2C5FFD3955B1

Q39215725-1664132E-CCAD-4498-97FA-D1379FBE2FAA

Q39215725-17569E56-2088-47F6-AAEA-4ECC52C41132

Q39215725-1E713DC4-A2ED-4231-AE73-E7B34AD2B111

Q39215725-21CC534A-DE18-4E4A-88EA-088AD7CDCF49

Q39215725-26594B1B-2FDE-4ABE-97A8-16122AF0BBCD

Q39215725-308EDC0E-A530-4435-A951-6BC8F3207179

Q39215725-357C63B1-EC93-4D1D-B0FA-6E2F010A4266

Q39215725-375860A8-4AC9-4721-9BAC-71BBF390CC21

P2888

Q39215725-9795D909-69AD-4E03-BF0D-EF5654CCF5A2

P304

Q39215725-0A2F70EF-ABBE-4194-9CB5-E3A98C5E6A92

P31

Q39215725-B321CD45-5D20-4418-ABA5-B0C1E5BF80CB

P356

Q39215725-2B63E48A-0DF9-4512-940E-574D275E6BA5

P433

Q39215725-CF95A14E-C518-4384-8B35-E6D2D1C6B54B

P478

Q39215725-D94A3981-7C23-462F-B30D-37642863A44F

P50

Q39215725-09191537-D971-493A-B9BD-D040C2D0A88D

Q39215725-2731BFF4-4108-4F0C-B601-F851DECDD4B6

Q39215725-AC4BEFA5-781C-453C-ABCE-E5CA95BCC5DC

Q39215725-F2F42640-A6D2-4521-94EA-961D892604B7

P577

Q39215725-CDB54977-1545-457C-8D21-5FC1385DB09B

P5875

Q39215725-F8D1CBE9-E236-4162-87AA-10FC5197A37A

P698

Q39215725-BA01EF25-2F22-4E8D-8945-43E1AB8A7D92

P921

Q39215725-66838CC3-E5A8-4292-8501-207936E93DA7

P356

S00125-012-2804-X

P1433

P1476

miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes

@en

P2093

A C K Chung

http://www.w3.org/2001/XMLSchema#string

F F Hou

http://www.w3.org/2001/XMLSchema#string

W Yang

http://www.w3.org/2001/XMLSchema#string

X Zhong

http://www.w3.org/2001/XMLSchema#string

Y Dong

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue

Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts

Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21

Inflammatory mechanisms of diabetic complications.

Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney.

Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.

Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells.

miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis

P2888

s00125-012-2804-x

P304

663-674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-012-2804-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234070016

http://www.w3.org/2001/XMLSchema#string

P698

23292313

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes